person · Reporting owner
French Glendon E. III
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EDAP TMS SAEDAP · Entity 6325 | Director | January 01, 2026 | January 10, 2026 |
| Pulmonx CorpLUNG · Entity 2359 | Director · President and CEO | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EDAP TMS SA
Report date January 01, 2026 · Filed January 10, 2026
This filing explicitly reported no securities owned.
Pulmonx Corp
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,720 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 4,098 · Balance 1,175,720 F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. F2: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 1,137,936 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Sale · Disposed 37,784 · Balance 1,137,936 F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 918,198 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 918,198 F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
F2: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026.
F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025.
F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 22:23 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 37,784 | $2.26 | $85,391.84 |
DisclosureSEC source: 0001805624-26-000004 · form4-09032026_100945.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,137,936 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 22:23 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,098 | $2.26 | $9,261.48 |
DisclosureSEC source: 0001805624-26-000004 · form4-09032026_100945.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,175,720 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. F2 · balance_after: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:15 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 13,511 | $1.57 | $21,212.27 |
DisclosureSEC source: 0001805624-26-000002 · form4-06032026_080643.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,178,162 F3 · kind: Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of June 2, 2025. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:15 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 38,467 | $1.54 | $59,239.18 |
DisclosureSEC source: 0001805624-26-000002 · form4-06032026_080643.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,191,673 F2 · kind: Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:15 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,171 | $1.54 | $6,423.34 |
DisclosureSEC source: 0001805624-26-000002 · form4-06032026_080643.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,230,140 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:06 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 58,368 | $1.43 | $83,466.24 |
DisclosureSEC source: 0001805624-26-000001 · form4-03052026_120316.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,409,511 F3 · kind: Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:06 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 6,737 | $1.43 | $9,633.91 |
DisclosureSEC source: 0001805624-26-000001 · form4-03052026_120316.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,467,879 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 00:06 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 2,708 | $1.43 | $3,872.44 |
DisclosureSEC source: 0001805624-26-000001 · form4-03052026_120316.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,474,616 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 00:51 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantPerformance Stock Units · Derivative | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001805624-25-000005 · form4-12042025_121243.xml · derivative · entry 5 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2028-12-01 F5 · derivative.exercise_price: Each Performance Stock Unit represents a contingent right to receive one share of the Issuer's common stock. The Performance Stock Units vest upon meeting the following two conditions: (a) upon the Issuer's common stock achieving a specified price per share and (b) with respect to 33% on the one year following the grant date of December 1, 2025 and the remainder in eight equal quarterly installments. F5 · derivative.exercise_date: Each Performance Stock Unit represents a contingent right to receive one share of the Issuer's common stock. The Performance Stock Units vest upon meeting the following two conditions: (a) upon the Issuer's common stock achieving a specified price per share and (b) with respect to 33% on the one year following the grant date of December 1, 2025 and the remainder in eight equal quarterly installments. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 00:51 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 1,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001805624-25-000005 · form4-12042025_121243.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,477,324 F3 · shares: Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 00:51 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 6,281 | $1.57 | $9,861.17 |
DisclosureSEC source: 0001805624-25-000005 · form4-12042025_121243.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,324 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 00:51 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 2,524 | $1.57 | $3,962.68 |
DisclosureSEC source: 0001805624-25-000005 · form4-12042025_121243.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,605 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 22:08 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 37,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015645 · form4-06042025_100638.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,029,127 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 2, 2025, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:14 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 20,000 | $7.85 | $157,000.00 |
DisclosureSEC source: 0001415889-25-008792 · form4-03212025_100324.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 991,974 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 12,417 | $8.76 | $108,772.92 |
DisclosureSEC source: 0001415889-25-005323 · form4-02242025_100254.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,011,974 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.60 to $9.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 43,036 | $8.14 | $350,313.04 |
DisclosureSEC source: 0001415889-25-005323 · form4-02242025_100254.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,024,391 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.60 to $8.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 17, 2025 Filed Jan 21, 2025 22:59 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 2,221 | $6.50 | $14,436.50 |
DisclosureSEC source: 0001415889-25-001819 · form4-01212025_100113.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,067,427 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 22:59 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 2,326 | $6.53 | $15,188.78 |
DisclosureSEC source: 0001415889-25-001819 · form4-01212025_100113.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,069,648 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 23:33 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 20,000 | $6.63 | $132,600.00 |
DisclosureSEC source: 0001415889-24-027785 · form4-11262024_111118.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,071,974 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 17, 2024 Filed Oct 21, 2024 21:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 20,000 | $6.52 | $130,400.00 |
DisclosureSEC source: 0001415889-24-025464 · form4-10212024_091042.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,091,974 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 12, 2024 Filed Sep 18, 2024 22:08 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 20,000 | $8.09 | $161,800.00 |
DisclosureSEC source: 0001415889-24-023654 · form4-09182024_100916.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,111,974 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.67 to $8.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:56 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 15,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015628 · form4-06052024_090637.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,131,974 F1 · shares: Represents grant of Restricted Stock Units ("RSU Grant") payable solely in common stock of the Issuer that vest on the earlier of (i) the one-year anniversary of the date of grant of June 3, 2024, or if such date is not a business day, then on the next business day, or (ii) the date of the Annual Meeting of the Stockholders for the year subsequent to the date such RSU Grant is made. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:15 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,947 | $9.06 | $35,759.82 |
DisclosureSEC source: 0001415889-24-006829 · form4-03052024_110301.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,116,758 F4 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:15 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,818 | $9.06 | $16,471.08 |
DisclosureSEC source: 0001415889-24-006829 · form4-03052024_110301.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,120,705 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:15 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,189 | $9.06 | $10,772.34 |
DisclosureSEC source: 0001415889-24-006829 · form4-03052024_110301.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,122,523 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021. F2 · balance_after: Includes 2,368 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on February 21, 2024. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 00:11 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 20,000 | $14.60 | $292,000.00 |
DisclosureSEC source: 0001415889-24-004241 · form4-02172024_120205.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,121,344 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 23:05 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 10,000 | $12.77 | $127,700.00 |
DisclosureSEC source: 0001415889-24-001651 · form4-01222024_110115.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,141,344 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.59 to $12.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 23:12 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 10,000 | $12.42 | $124,200.00 |
DisclosureSEC source: 0001209191-23-059614 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,151,344 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.28 to $12.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,045 | $10.34 | $41,825.30 |
DisclosureSEC source: 0001209191-23-057506 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,344 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,591 | $10.34 | $16,450.94 |
DisclosureSEC source: 0001209191-23-057506 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,165,389 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,040 | $10.34 | $10,753.60 |
DisclosureSEC source: 0001209191-23-057506 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,166,980 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,921 | $10.01 | $39,249.21 |
DisclosureSEC source: 0001209191-23-048487 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,168,020 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,575 | $10.01 | $15,765.75 |
DisclosureSEC source: 0001209191-23-048487 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,171,941 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,031 | $10.01 | $10,320.31 |
DisclosureSEC source: 0001209191-23-048487 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,173,516 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 22:30 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 15,000 | $12.68 | $190,200.00 |
DisclosureSEC source: 0001209191-23-043254 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,174,547 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.56 to $13.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:08 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 10,000 | $12.68 | $126,800.00 |
DisclosureSEC source: 0001209191-23-038576 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,189,547 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.52 to $12.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:38 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,924 | $11.48 | $45,047.52 |
DisclosureSEC source: 0001209191-23-033999 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,199,547 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:38 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,577 | $11.48 | $18,103.96 |
DisclosureSEC source: 0001209191-23-033999 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,203,471 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:38 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,032 | $11.49 | $11,857.68 |
DisclosureSEC source: 0001209191-23-033999 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,205,048 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:58 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantEmployee Stock Option (right to buy) · Derivative | 356,300 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001209191-23-016000 · doc4.xml · derivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,300 Underlying: Common Stock · 356,300 shares Expires 2033-02-28 F5 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:58 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 173,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016000 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206,080 F4 · shares: Represents grant of Restricted Stock Units payable solely in common stock of the Issuer that vest over four years in equal quarterly installments beginning on March 1, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:58 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,711 | $11.03 | $18,872.33 |
DisclosureSEC source: 0001209191-23-016000 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,580 F3 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 1, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:58 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,184 | $11.03 | $13,059.52 |
DisclosureSEC source: 0001209191-23-016000 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,291 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. F2 · balance_after: Includes 1,162 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on February 15, 2023. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 00:01 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 2,195 | $5.93 | $13,016.35 |
DisclosureSEC source: 0001209191-22-059855 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,313 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 00:01 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,436 | $5.93 | $8,515.48 |
DisclosureSEC source: 0001209191-22-059855 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,508 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 01:04 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-22-056871 · doc4.xml · derivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,249 Underlying: Common Stock · 10,000 shares Expires 2030-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 01:04 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 10,000 | $2.20 | $22,000.00 |
DisclosureSEC source: 0001209191-22-056871 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 21:23 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0001209191-22-050572 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,944 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,926 | $17.87 | $34,417.62 |
DisclosureSEC source: 0001209191-22-048780 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,944 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,014 | $17.87 | $18,120.18 |
DisclosureSEC source: 0001209191-22-048780 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,870 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.